162 related articles for article (PubMed ID: 10353046)
21. Crystals and tablets in the Spanish ecstasy market 2000-2014: Are they the same or different in terms of purity and adulteration?
Vidal Giné C; Ventura Vilamala M; Fornís Espinosa I; Gil Lladanosa C; Calzada Álvarez N; Fitó Fruitós A; Rodríguez Rodríguez J; Domíngo Salvany A; de la Torre Fornell R
Forensic Sci Int; 2016 Jun; 263():164-168. PubMed ID: 27129144
[TBL] [Abstract][Full Text] [Related]
22. Selective neurocognitive deficits associated with multiple doses of ecstasy/MDMA: a reply to Cole.
Fox HC; Parrott AC
J Psychopharmacol; 2003 Jun; 17(2):242-4. PubMed ID: 12870575
[No Abstract] [Full Text] [Related]
23. Impurity profiling of seized MDMA tablets by capillary gas chromatography.
Palhol F; Boyer S; Naulet N; Chabrillat M
Anal Bioanal Chem; 2002 Sep; 374(2):274-81. PubMed ID: 12324849
[TBL] [Abstract][Full Text] [Related]
24. 3,4-Methylenedioxymethamphetamine quantification via benchtop
Frinculescu A; Maier AFG; Shine T; Ramsey J; Araneda JF; Riegel SD; Frascione N; Abbate V
J Pharm Biomed Anal; 2022 May; 214():114728. PubMed ID: 35349940
[TBL] [Abstract][Full Text] [Related]
25. Monitoring ecstasy content in France: results from the National Surveillance System 1999-2004.
Giraudon I; Bello PY
Subst Use Misuse; 2007; 42(10):1567-78. PubMed ID: 17918027
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological content of tablets sold as "ecstasy": results from an online testing service.
Tanner-Smith EE
Drug Alcohol Depend; 2006 Jul; 83(3):247-54. PubMed ID: 16364567
[TBL] [Abstract][Full Text] [Related]
27. Development and application of a high-performance liquid chromatography method using monolithic columns for the analysis of ecstasy tablets.
Mc Fadden K; Gillespie J; Carney B; O'Driscoll D
J Chromatogr A; 2006 Jul; 1120(1-2):54-60. PubMed ID: 16466734
[TBL] [Abstract][Full Text] [Related]
28. Qualitative transformations of street-seized ecstasy over a decade: A case study in Rio de Janeiro (Brazil).
Antonio ADS; Wurzler GT; Bhering CA; de Oliveira AS; Cohen LSDA; de Oliveira MAM; de Aquino Neto FR; Vanini G
J Forensic Sci; 2024 Jul; 69(4):1198-1211. PubMed ID: 38691107
[TBL] [Abstract][Full Text] [Related]
29. The prevalence of MDMA/MDA in both hair and urine in drug users.
Han E; Yang W; Lee J; Park Y; Kim E; Lim M; Chung H
Forensic Sci Int; 2005 Aug; 152(1):73-7. PubMed ID: 15939177
[TBL] [Abstract][Full Text] [Related]
30. Screening experiments of ecstasy street samples using near infrared spectroscopy.
Sondermann N; Kovar KA
Forensic Sci Int; 1999 Dec; 106(3):147-56. PubMed ID: 10680063
[TBL] [Abstract][Full Text] [Related]
31. "Saturday night fever": ecstasy related problems in a London accident and emergency department.
Williams H; Dratcu L; Taylor R; Roberts M; Oyefeso A
J Accid Emerg Med; 1998 Sep; 15(5):322-6. PubMed ID: 9785160
[TBL] [Abstract][Full Text] [Related]
32. Assessment of chronic exposure to MDMA in a group of consumers by segmental hair analysis.
Pichini S; Poudevida S; Pujadas M; Menoyo E; Pacifici R; Farré M; de la Torre R
Ther Drug Monit; 2006 Feb; 28(1):106-9. PubMed ID: 16418703
[TBL] [Abstract][Full Text] [Related]
33. Instability of the ecstasy market and a new kid on the block: mephedrone.
Brunt TM; Poortman A; Niesink RJ; van den Brink W
J Psychopharmacol; 2011 Nov; 25(11):1543-7. PubMed ID: 20826554
[TBL] [Abstract][Full Text] [Related]
34. Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users.
Morefield KM; Keane M; Felgate P; White JM; Irvine RJ
Addiction; 2011 Jul; 106(7):1293-300. PubMed ID: 21320226
[TBL] [Abstract][Full Text] [Related]
35. Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 - A potential risk to users?
Couchman L; Frinculescu A; Sobreira C; Shine T; Ramsey J; Hecht M; Kipper K; Holt D; Johnston A
Drug Test Anal; 2019 Aug; 11(8):1172-1182. PubMed ID: 31009168
[TBL] [Abstract][Full Text] [Related]
36. Putting an Ecstasy test kit to the test: harm reduction or harm induction?
Murray RA; Doering PL; Boothby LA; Merves ML; McCusker RR; Chronister CW; Goldberger BA
Pharmacotherapy; 2003 Oct; 23(10):1238-44. PubMed ID: 14594341
[TBL] [Abstract][Full Text] [Related]
37. Development of a high-speed MALDI-triple quadrupole mass spectrometric method for the determination of 3,4-methylenedioxymethamphetamine (MDMA) in oral fluid.
Poetzsch M; Steuer AE; Hysek CM; Liechti ME; Kraemer T
Drug Test Anal; 2016 Feb; 8(2):235-40. PubMed ID: 25990956
[TBL] [Abstract][Full Text] [Related]
38. A contribution to the chemical profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets.
Gimeno P; Besacier F; Chaudron-Thozet H; Girard J; Lamotte A
Forensic Sci Int; 2002 Jun; 127(1-2):1-44. PubMed ID: 12098525
[TBL] [Abstract][Full Text] [Related]
39. Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion.
Farah R; Farah R
Pediatr Emerg Care; 2008 Sep; 24(9):615-7. PubMed ID: 18797371
[TBL] [Abstract][Full Text] [Related]
40. Ecstasy analysis by monolithic materials-capillary electrochromatography.
Choodum A; Thavarungkul P; Kanatharana P; Smith NW
Anal Sci; 2009 Apr; 25(4):517-22. PubMed ID: 19359792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
